BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
20 hedge funds and large institutions have $6.48M invested in BRAINSTORM CELL THERAPUTC in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 5 closing their positions.
5% less funds holding
Funds holding: 21 → 20 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
40% less capital invested
Capital invested by funds: $10.7M → $6.48M (-$4.23M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$378K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$178K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$98.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$17.4K |
| 5 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.65M |
| 2 |
SIM
Spark Investment Management
New York
|
-$262K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$54K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$51K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$47.7K |
BCLI Hedge Fund Activity: Q2 2015 in Review
20 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2015, worth a combined $6.48M — down 40% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BCLI and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $378K. The largest seller was Sabby Management, cutting an estimated $2.65M.
- 20 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2015, down from 21 in Q1 2015.
- Funds reported $6.48M of BRAINSTORM CELL THERAPUTC stock for Q2 2015, down 40% quarter-over-quarter.
- 4 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2015 and 5 closed out, a net change of -1 holder.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2015 was Vanguard Group, an estimated $378K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2015 was Sabby Management, an estimated $2.65M sold.
Based on aggregated 13F filings for Q2 2015.